Sino-foreign Co-operative Joint Venture ContractLicense Agreement • May 8th, 2017 • Kite Pharma, Inc. • Biological products, (no disgnostic substances)
Whereas Kite is a clinical-stage biotechnology company engaged, through its Affiliates, in the research, development and commercialization of novel cellular and other immunotherapies, including for the treatment of cancer.
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • May 8th, 2017 • Kite Pharma, Inc. • Biological products, (no disgnostic substances) • California
This COLLABORATION AND LICENSE (this “Agreement”) effective as of January 5, 2017 (the “Effective Date”), is by and between KITE PHARMA EU B.V., a corporation organized and existing under the laws of The Netherlands having a place of business at Science Park 408, 1098 XH Amsterdam (“Kite”) and DAIICHI SANKYO COMPANY, LIMITED, a corporation organized and existing under the laws of Japan, having a place of business at 3-5-1 Nihonbashi-honcho, Chuo-ku, Tokyo 103-8426 (“DS”). Kite is a wholly-owned indirect subsidiary of Kite Pharma, Inc. (“ParentCo”). Kite and DS may be referred to herein each as a “Party” and collectively as the “Parties”.
